LifeArc, a UK-based medical research charity, is investing £1.5 million into Caldan Therapeutics Limited, a company developing novel therapeutics for the treatment of metabolic diseases. 

Through LifeArc’s funding Caldan will be able to progress potentially groundbreaking new treatments for NASH, a progressive form of non-alcohol related fatty liver disease.

NASH is now considered to be one of the major causes of cirrhosis of the liver; its prevalence among UK adults is estimated as high as 1 in 8 people. This could present a huge burden on the NHS in the future, with an increasing number of people requiring care for cirrhosis or needing a liver transplant.

Read LifeArc’s press release


Back to e-newsletter